PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Clinical trials for PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested in battle against Tough-to-Treat gynecologic cancers
Disease control OngoingThis early-stage study is testing a combination of two drugs, niraparib (a pill) and copanlisib (an IV infusion), for women whose ovarian, endometrial, or related cancers have returned after prior treatment. The main goals are to find the safest dose of this combination and to le…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for Hard-to-Treat ovarian cancer? early trial tests drug combo
Disease control OngoingThis early-stage study is testing the safety and best dose of a new drug called ipatasertib when given alongside standard chemotherapy drugs (paclitaxel and carboplatin) to patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if adding …
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Major trial aims to tame dozens of rare, neglected cancers with immune power combo
Disease control OngoingThis large national trial is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help control over 50 different types of rare cancers that have few or no standard treatment options. It enrolled over 800 adults whose rare cancers had progressed …
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Race to control tough ovarian cancer: Three-Way drug showdown
Disease control OngoingThis study is testing which combination of three drugs works best to control recurrent ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to standard platinum-based chemotherapy. It involves 444 patients and compares a standard two-drug combo agains…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for Tough-to-Treat ovarian cancers in early trial
Disease control OngoingThis early-stage study is testing a new two-drug combination for women with ovarian cancer that has returned after previous treatment. The main goal is to find the safest and most effective dose of an experimental pill (peposertib) when given with a standard chemotherapy drug. Re…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope: testing targeted drug before surgery for aggressive ovarian cancer
Disease control OngoingThis early study is testing whether a drug called olaparib can help shrink tumors before surgery in people newly diagnosed with advanced ovarian cancer that has a BRCA gene mutation. The trial involves about 15 participants who will take olaparib pills for up to two months before…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
Scientists test Immune-Boosting combo to fight returning ovarian cancer
Disease control OngoingThis study is testing if a two-drug combination works better than a single drug to control recurrent ovarian, fallopian tube, or peritoneal cancer that still responds to platinum chemotherapy. It compares a targeted pill (olaparib) alone to the pill plus an immunotherapy drug (tr…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New targeted attack on tough ovarian cancer tested against standard care
Disease control OngoingThis study is for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. It compares a new two-drug combination (bevacizumab + anetumab ravtansine) against a standard two-drug combination (bevacizumab + paclit…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
Scientists test new drug to weaken ovarian cancer before surgery
Knowledge-focused OngoingThis early study is testing if a drug called adavosertib, given before surgery, can affect the DNA of tumors in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. The main goal is to learn how the drug changes the cancer cells at a molecular level, whic…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC